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Background: Mouth occlusion pressure measurement is widely used for assessment of
respiratory muscle function, particularly in patients with respiratory failure. However, its
predictive value for long-term survival remains largely unexplored.
Methods: In 464 patients with chronic hypercapnic respiratory failure (CHRF) due to
various underlying disorders and receiving non-invasive ventilation (NIV), maximal
inspiratory mouth pressure (PImax), mouth occlusion pressure at 100ms during quiet
breathing (P0.1) and the ratio P0.1/PImax were assessed prior to and after treatment
including NIV. Baseline data and changes at follow-up were used to evaluate their
predictive value for long-term survival.
Results: Overall, median (quartiles) P0.1 was 177.0 (109.2;287.0) %pred, PImax 35.0
(24.0;47.0) %pred, and P0.1/PImax 564.0 (275.7;1082.3) %pred. In multivariate analyses,
P0.1 was related to airflow obstruction, lung hyperinflation, haemoglobin (Hb) and
leukocytes, and PImax to airflow obstruction and hyperinflation (po0.05 each). All-causeElsevier Ltd. All rights reserved.
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S. Budweiser et al.2344mortality during follow-up (median 31.6 months) was 31.5%. Survival was associated with
age, body-mass index (BMI), lung function, leukocytes, Hb, PImax, P0.1 and P0.1/PImax
(po0.01 each, univariate). Among these multivariate Cox regression identified age, BMI,
FEV1, leukocytes and P0.1/PImax as independent predictors (po0.05 each). Furthermore,
the decrease of P0.1/PImax at follow-up was associated with improved survival in patients
with high baseline P0.1/PImax (450th or 75th percentile; po0.05).
Conclusions: In patients with CHRF and current NIV therapy, P0.1/PImax was an
independent predictor of long-term survival, in addition to previously established risk
factors. Moreover, a decrease in P0.1/PImax after treatment including NIV was associated
with an improved survival in patients with high baseline P0.1/PImax values.
& 2007 Elsevier Ltd. All rights reserved.Introduction
A variety of diseases can evoke chronic alveolar hypoventi-
lation and a persistent elevation of arterial carbon dioxide
tension (PaCO2), which defines chronic hypercapnic respira-
tory failure (CHRF). Pathophysiologically, CHRF results from
disturbances in the respiratory pump by mechanical dis-
advantage, central nervous system abnormalities or respira-
tory muscle dysfunction.1 Chronic hypercapnia is commonly
considered an ominous prognostic sign, but the correspond-
ing hypoventilation could also be favourable in preventing
respiratory muscle fatigue.2 Unfortunately, the reliable
assessment of respiratory muscle function by classical
physiological techniques requires sophisticated, invasive
procedures and is thus not suited for clinical practice.3,4
Instead, a routine, non-invasive measure of inspiratory
muscle strength is provided by maximal inspiratory mouth
occlusion pressure (PImax), which is often considered in
therapeutic decisions5 and in monitoring pharmacologic
treatment,6 rehabilitation programs7 or nutritional interven-
tions.8,9 Comprehensive studies described an association
between PImax and long-term mortality in chronic obstructive
pulmonary disease (COPD)8,9 and in cardiovascular disease.10
Inspiratory mouth occlusion pressure at 100ms during quiet
breathing (P0.1) is a marker of neuromuscular ventilatory drive
which is independent of the patient’s effort.4 P0.1 and the
ratio of P0.1/PImax have been suggested as predictors of
impending respiratory muscle fatigue and extubation suc-
cess.11 Therefore, it may be hypothesized that these measures
also play a role for long-term outcome in patients with CHRF
undergoing non-invasive ventilation (NIV).
Based on these considerations, the present study focussed
on the prognostic value of PImax, P0.1 and P0.1/PImax in
patients with CHRF of different origin undergoing NIV. We
assessed both whether baseline values and changes after
treatment including NIV were associated with long-term
mortality. In addition, the prognostic value of these
measures was compared with that of markers established
in chronic respiratory diseases, including lung function,
body-mass index (BMI) and laboratory parameters.
Materials and methods
Study population
We included consecutive patients receiving long-term NIV to
treat CHRF due to various underlying disorders, who weredischarged from the Donaustauf Hospital, University of
Regensburg, between October 1995 and December 2005.
Patients o18 years of age or discharged with invasive
ventilation were excluded, as well as patients in whom
mouth occlusion pressure had not been determined prior to
initiation of long-term NIV. The underlying disorders
comprised COPD and restrictive disorders (RD) including
obesity-hypoventilation syndrome (OHS), chest wall diseases
(CWD), neuromuscular disorders (NMD), or interstitial lung
disease (ILD).
The diagnosis of COPD was based on the guidelines of the
American Thoracic Society (ATS).12 OHS was defined by a BMI
430 kg/m2, daytime PaCO2X45mmHg, and clinical symp-
toms of CHRF in the absence of other known causes of
hypoventilation.13
The decision to initiate NIV was based on clinical
symptoms such as dyspnoea, fatigue and morning headache,
as well as elevated PaCO2. Exacerbations were defined as
worsening of respiratory symptoms, elevated laboratory
markers of inflammation, documented treatment with
antibiotics, or an increase in the dose of oral steroids. The
study was approved by the local Ethics Committee.Assessments
Prior to NIV, daytime blood gases were determined from
the hyperaemic earlobe, if possible without additional
oxygen, otherwise in the presence of supplemental oxygen
(Rapidlab, Bayer Inc., East Walpole, MA, USA). Spirometry
and body plethysmography were performed according to ATS
guidelines14 using ERS reference values.15
During the determination of mouth occlusion pressure,
subjects were sitting and wearing a nose clip. All breathing
manoeuvres were carefully explained to the patients by
nurses with specific experience in P0.1 and PImax man-
oeuvres. A rubber flanched mouthpiece (type ‘‘silicone’’,
Viasys Healthcare GmbH, Wu¨rzburg, Germany) fitting tightly
inside the lips to prevent leakage was used and attached to
an elbow tube (451, reinforced; Viasys Healthcare GmbH,
Wu¨rzburg, Germany), having a defined leak of 2mm
diameter and 30mm length to prevent glottic closure during
PImax measurement.
4 Pressures were recorded with a fast
differential pressure transducer (range 730 kPa, resolution
0.01 kPa; frequency response 50Hz, electronically filtered
sample frequency 200Hz; Viasys Healthcare GmbH, Wu¨rz-
burg, Germany), with a shutter closure time o10ms. P0.1
was sampled after the first 100ms of inspiration against the
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from three qualitatively acceptable measurements was
registered. PImax was measured from residual volume at
maximal inspiratory effort16 while recording peak inspira-
tory pressures. A reproducibility of at least 5% was required
and the highest value of at least three attempts was chosen.
Reference values were taken from data obtained by the
same device.17
Standard blood parameters and the level of C-reactive
protein (CRP) were assessed by established procedures.
Body weight was determined on the first day in the hospital
and BMI calculated as weight/height2. Additionally, treat-
ments other than NIV and significant comorbidities were also
documented.
NIV technique and settings
NIV was applied in a pressure- or volume-cycled assist-
controlled mode while targeting a maximal reduction of
PaCO2.
18 Oxygen was supplemented to maintain arterial
oxygen saturation 490%. NIV was applied via nasal, full-
face, or custom-made masks (the latter in cases of
persistent leakage and/or nasal ulceration). If drying of
the mucosa developed, a humidification system was in-
stalled. The Onyx plus (Nellcor Puritan Bennett Inc;
Courtaboef Cedex, France), the BIPAP synchrony ST (Re-
spironics Inc; Murrysville, PA, USA), and the Smart/Twin Air
(Airox Inc., Pau, France) were used for NIV.
Follow-up
Patients were scheduled for re-admission to the hospital six
months after initiation of NIV. Adherence to NIV was
assessed via the time counter of the ventilator. Ventilation
parameters were adjusted according to blood gases and
nocturnal oxygen saturation. Mouth occlusion pressures,
lung function, blood gases and laboratory parameters were
determined in the same manner as for inclusion. For survival
analysis, patients were followed until death or until the end
of the study period on January 1, 2006. Information on
survival was obtained from the patient’s relatives and/or
family doctor.
Statistical analysis
For data description median values and quartiles are given.
To compare baseline characteristics between groups, the
Mann–Whitney U-test was used, and to compare baseline
and follow-up values, we employed the Wilcoxon test. The
association of mouth occlusion pressures with other vari-
ables was assessed by multivariate regression analysis.
Correlations were quantified by Spearman’s rank coefficient.
Survival was calculated by the Kaplan–Meier method
starting from initiation of NIV to the closing date of January
1st, 2006. Cut-off values were derived from rounded median
values or 25th or 75th percentiles. The predictive value of
each single variable for all-cause mortality was analysed by
univariate regression using the log-rank test. Variables
significant in univariate analyses were fed into a stepwise
multivariate Cox regression analysis to identify independent
predictors, using an entry level of p ¼ 0.05 and a removallevel of 0.10. For all tests, a p-value o0.05 was considered
statistically significant. Calculations were performed using
SPSS (V. 12.0, Chicago, IL, USA).
Results
Study population
Among 753 patients discharged with NIV, data of mouth
occlusion pressure obtained prior to initiation of NIV were
available for 464 patients (Table 1). Patients suffered from
COPD (n ¼ 227; 48.9%), OHS (n ¼ 109; 23.5%), CWD (n ¼ 75;
16.2%), NMD (n ¼ 39; 8.4%), or ILD (n ¼ 14; 3.0%). At the
time of NIV initiation, 81 of the 464 patients (17.5%)
experienced an exacerbation and 147 (31.7%) were already
receiving long-term oxygen therapy (LTOT), while at
discharge 344 patients (74.1%) had LTOT in addition to NIV.
Ventilator settings upon discharge showed a median (quar-
tiles) expiratory pressure of 4 (3; 5)mbar, inspiratory
pressure of 21 (18; 24)mbar, and respiratory frequency of
20 (16; 22) /min.
Comorbidities included hypertension (59.7%), diabetes
(20.7%), coronary heart disease or left heart failure (26.3%),
and atrial fibrillation (7.8%). In patients with COPD, therapy
upon discharge included b2-adrenoceptor agonists in 98.7%
of patients, as well as anticholinergics (79.7%), inhaled
corticosteroids (60.4%) and theophylline (68.7%).
Mouth occlusion pressure at baseline
In patients with NMD and OHS, PImax, P0.1 and P0.1/PImax
levels were significantly different from those with COPD,
while in patients with CWD only P0.1/PImax %pred differed
from that of COPD (Table 2).
Multivariate regression analysis showed specific airway
resistance (sRaw), residual volume-to-total lung capacity
(RV/TLC), forced expiratory volume in 1 s (FEV1) (po0.001
each), haemoglobin (Hb) (p ¼ 0.005), leukocytes and FEV1/
inspiratory vital capacity (IVC) (po0.05 each) to be
independently related to P0.1 %pred in the total group of
patients. Correspondingly, P0.1 %pred correlated with FEV1
(r ¼ 0.74; po0.001), RV/TLC (r ¼ 0.61; po0.001) and
sRaw (r ¼ 0.48; po0.001). PImax %pred was independently
associated only with RV/TLC and FEV1/IVC (po0.001 each).
Follow-up visit
The follow-up visit occurred 5.8 (3.9; 7.6) months after
initiation of NIV. Within this time interval, 27 patients (5.8%)
had died and an additional 11 patients (2.4%) had stopped
long-term NIV. Sixteen patients (3.4%) were not re-admitted
on schedule, and in 14 patients (3.0%) mouth occlusion
pressures were not re-assessed. Thus, pressures were
available for 396 patients after initiation of NIV. The
duration of ventilator use which could be assessed in 376
patients (94.9%) was 6.2 (4.5; 8.0) h/day and did not differ
significantly between groups. Compared to the values
obtained prior to NIV, PImax changed (median D ¼ +0.61 kPa
or +5.5 %pred; po0.001), as well as P0.1 (median
D ¼ 0.011 kPa or 6.4 %pred; po0.05) and P0.1/PImax
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Table 1 Baseline characteristics and their prognostic value according to univariate survival analyses (n ¼ 464).
Variable Median (quartiles) p-Value HR 95%-CI of HR
Age (yr) 63.1 (55.2; 70.0) o0.001 0.463 0.336–0.643
BMI (kg/m2) 29.0 (23.3; 37.1) o0.001 3.309 2.335–4.492
Sex (m/f) 287/176 0.031 1.473 1.034–2.014
Exacerbation (y/n) 81/383 0.004 0.578 0.327–0.814
Haemoglobin (g/dL) 14.7 (12.9; 16.1) o0.001 1.746 1.286–2.489
Leukocytes (103/mL) 8.1 (6.8; 10.1) o0.001 0.544 0.390–0.749
CRP (mg/dL) 5.4 (4.5; 20.4) 0.5430 0.905 0.654–1.251
sRaw (kPa s) 2.4 (1.3; 4.5) o0.001 0.512 0.369–0.712
RV/TLC (%) 66.0 (55.6; 75.3) o0.001 0.363 0.254–0.498
FEV1 (L) 0.9 (0.7; 1.3) o0.006 1.763 1.277–2.442
FEV1 (%pred) 37.5 (27.5; 49.9) 0.004 1.619 1.173–2.240
FEV1/IVC (%) 63.0 (47.0; 76.0) 0.006 1.586 1.144–2.182
pH 7.41 (7.38; 7.44) 0.080 0.751 0.541–1.036
PaO2 (mmHg) 59.0 (51.0; 68.0) 0.168 0.797 0.577–1.101
PaCO2 (mmHg) 55.0 (49.0; 61.0) 0.193 0.807 0.585–1.115
BE (mmol/L) 7.9 (5.2; 10.9z) 0.090 0.757 0.546–1.044
P0.1 (kPa) 0.41 (0.28; 0.58) 0.032 0.704 0.508–0.971
P0.1 (%pred) 177.0 (109.2; 287.0) o0.001 0.513 0.373–0.713
PImax (kPa) 3.6 (2.5; 4.9) 0.005 1.588 1.151–2.198
PImax (%pred) 35.0 (24.0; 47.0) 0.013 1.505 1.088–2.076
P0.1/PImax 0.12 (0.07; 0.19) o0.001 0.559 0.405–0.774
P0.1/PImax (%pred) 564.0 (275.7; 1082.3) o0.001 0.379 0.277–0.532
Definition of abbreviations: HR ¼ hazard ratio; CI ¼ Confidence interval; BMI ¼ body-mass index; CRP ¼ C-reactive protein;
sRaw ¼ specific airway resistance; TLC ¼ total lung capacity; RV ¼ residual volume; FEV1 ¼ forced expiratory volume in 1 s; IVC ¼ vital
capacity; PaO2 ¼ arterial oxygen tension; PaCO2 ¼ arterial carbon dioxide tension; BE ¼ base excess; P0.1 ¼ mouth occlusion pressure
at 100ms and PImax ¼ maximal inspiratory mouth occlusion pressure. Blood gas values were obtained either without (n ¼ 176) or with
oxygen supplementation (n ¼ 288) of 2.0 (1.0; 2.0) L/min.
According to Kaplan–Meier analysis (based on log-rank value) with cut-off values referring to the median.
zSignificant (po0.01) difference in survival according to Kaplan–Meier analysis using the respective quartile as cut-off value.
Table 2 Baseline values of mouth occlusion pressure in different diseases (n ¼ 464).
n P0.1 P0.1 PImax PImax P0.1/PImax P0.1/PImax
(kPa) (%pred) (kPa) (%pred) (%pred)
COPD 227 0.46 222.3 3.6 34.1 0.14 704.8
(0.35;0.65) (146.0;336.5) (2.5;4.8) (24.0;45.0) (0.09;0.20) (393.0;1195.7)
RD 237 0.36z 130.0z 3.8 35.0 0.10z 404.0z
(0.24;0.54) (80.3;222.8) (2.5;5.5) (23.5;51.2) (0.05;0.18) (205.5;889.5)
OHS 109 0.34z 95.9z 4.8z 46.0z 0.08z 221.7z
(0.22;0.50) (60.4;133.2) (3.4;7.2) (32.0;68.5) (0.03;0.12) (99.0;382.5)
CWD 75 0.46 249.3 3.1 29.0* 0.15 813.0*
(0.32;0.62) (154.0;388.0) (2.2; 4.2) (19.5;40.1) (0.09;0.25) (436.6;1744.0)
NMD 39 0.25z 124.6z 2.8z 25.7z 0.11* 481.0*
(0.14;0.37) (65.2;179.0) (1.6;3.5) (15.0;34.0) (0.05;0.17) (154.0;388.0)
ILD 14 0.56 295.3 2.5 24.0 0.17 925.0
(0.29;0.81) (132.1;443.5) (1.9; 4.5) (18.1;43.4) (0.12;0.24) (710.2;1259.5)
The table shows median values and quartiles (in parentheses). Definition of abbreviations: COPD ¼ chronic obstructive pulmonary
diseases; RD ¼ restrictive diseases: OHS ¼ obesity-hypoventilation syndrome, CWD ¼ chest wall disease, NMD ¼ neuromuscular
disorders; ILD ¼ interstitial lung disease, P0.1 ¼ mouth occlusion pressure at 100ms; PImax ¼ maximal inspiratory mouth occlusion
pressure. Significant difference compared with the COPD group by the Mann–Whitney U-test: *po0.05; ypo0.01; zpo0.001.
S. Budweiser et al.2346
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Figure 1 Percentual changes in PImax, P0.1, and P0.1/PImax (median) at follow-up in the different disease groups. *po0.05; ypo0.01;
zpo0.001.
Figure 2 Kaplan–Meier curves for each disease. Survival rates
of patients with COPD were worse compared to OHS (po0.001)
and CWD (p ¼ 0.001) but better than those of patients with ILD
(po0.001). Definition of abbreviations: COPD ¼ chronic ob-
structive pulmonary disease; RD ¼ restrictive diseases compris-
ing; OHS ¼ obesity-hypoventilation syndrome; CWD ¼ chest
wall disease; NMD ¼ neuromuscular disorders and ILD ¼
interstitial lung disease.
Mouth occlusion pressure in respiratory failure 2347(median D ¼ 0.019 or 71.3 %pred; po0.001). Figure 1
illustrates the changes observed within the different groups.
In addition, significant increases in pH, arterial oxygen
tention (PaO2), FEV1, and decreases in PaCO2, base excess
(BE), sRaw, RV/TLC, CRP and Hb (po0.05 each) occurred.
Long-term survival
In the total group of patients the observation time between
initiation of NIV and the end of the study period, or until
patients died, was 31.1 (15.5; 57.4) months. Within this
period, 53 patients (11.4%) ceased NIV and 147 patients
(31.7%) died. Deaths resulted predominantly from respira-
tory causes (n ¼ 122; 83.0%), including respiratory or right
heart failure, pulmonary embolism and pneumothorax.
Kaplan–Meier curves for each disease group are given in
Figure 2. Survival rates in patients with COPD were lower
than in patients with OHS (po0.001; hazard ratio
(HR) ¼ 4.50; 95%-confidence interval (CI) 2.06–4.47) and
CWD (po0.001; HR ¼ 2.53; 95%-CI 1.46–3.26), but higher
than in ILD (po0.001; HR ¼ 0.36; 95%-CI 0.07–0.49).
Prognostic value of mouth occlusion pressure
In univariate analyses, PImax, P0.1 and P0.1/PImax were
predictive for long-term survival in the total group of
patients (Table 1, Figure 3a–c). P0.1/PImax was also pre-
dictive when analysed either for COPD (n ¼ 227; median
705%pred) or for RD (n ¼ 237; median 404 %pred) sepa-
rately, using the median of each group as the cut-off value.
Corresponding hazard ratios were 0.38 (po0.0001;
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Table 3 Prognostic value of baseline parameters according to stepwise Cox multivariate regression analysis.
Cut-off B SE Exp (B) 95%-CI of Exp(B) p-Value
Age (yr) 63.0 0.429 0.193 1.535 1.052–2.240 0.026
BMI (kg/m2) 29.0 0.941 0.214 0.390 0.256–0.594 o0.001
Leukocytes (103/mL) 8.1 0.597 0.184 1.817 1.268–2.604 0.001
FEV1 (%pred) 37.5 0.603 0.239 1.827 1.144–2.920 0.012
P0.1/PImax (%pred) 564.0 0.640 0.217 1.897 1.241–2.901 0.003
For abbreviations see Table 1. B ¼ estimate of regression coefficient, SE ¼ standard error of estimate.
Figure 3a–c . Prognostic value of mouth occlusion pressures in terms of PImax %pred (p ¼ 0.013; HR ¼ 1.51; 95%-CI 1.09–2.08), P0.1
%pred (po0.001; HR ¼ 0.51; 95%-CI 0.37–0.71), and P0.1/PImax %pred (po0.001; HR ¼ 0.38. 95%-CI 0.28–0.53) in the total group of
patients, using the median of the respective variable as the cut-off value. Definition of abbreviations: P0.1 ¼ mouth occlusion
pressure at 100ms; PImax ¼ maximal inspiratory mouth occlusion pressure.
S. Budweiser et al.2348HR ¼ 0.38; 95%-CI 0.23–0.52) and 0.48 (p ¼ 0.0116;
HR ¼ 0.48; 95%-CI 0.28–0.85). When excluding patients with
NMD and OHS and using the corresponding median P0.1
(232 %pred) as cut-off value, P0.1 was still highly predictive
for mortality (n ¼ 316; HR ¼ 0.62; 95%-CI 0.43–0.87;
p ¼ 0.0061). Very similar results were obtained for P0.1/
PImax when using its median cut-off value of 733 %pred
(HR ¼ 0.58; 95%-CI 0.40–0.82; p ¼ 0.0022). Moreover, when
excluding patients with OHS to account for a potential biasregarding body mass, BMI was still associated with long-term
survival (n ¼ 355; HR 2.40; 95%-CI 1.72–3.42; po0.0001).
In stepwise multivariate Cox regression, BMI, leukocytes,
age, FEV1 and P0.1/PImax %pred remained as indepen-
dent predictors of mortality in the total group of patients
(Table 3). Cox regression plots were also performed using
the quartiles of P0.1/PImax %pred (Figure 4).
Furthermore, the changes in P0.1/PImax %pred after the
onset of NIV treatment were evaluated with regard to
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Mouth occlusion pressure in respiratory failure 2349mortality. The change in P0.1/PImax was not significantly
associated with survival when its median value (71.3%pred)
in the total group of patients was analysed. However, when
only patients with baseline values of P0.1/PImax X the 50thFigure 4 Prognostic value of P0.1/PImax %pred according to
quartiles within the total group of patients. Significant
differences were detected between quartiles 1 and 2
(po0.05), 1 and 3 (po0.001), 1 and 4 (po0.001), between
quartiles 2 and 3 (po0.01) and 2 and 4 (po0.001) but not
between quartiles 3 and 4 (p ¼ 0.61)
Figure 5 Prognostic value of changes in P0.1/PImax %pred which
were either above or below the median change (71.3%) in
patients showing baseline P0.1/PImax %pred 4 the 75th popula-
tion percentile (po0.01).percentile (564%pred) or X the 75th percentile (1085%pred)
were considered, these changes were significantly associated
with mortality (Figure 5). The corresponding median changes
of P0.1/PImax in these patients were 294.6%pred and
605.0%pred, respectively. Neither the duration of ventilator
use nor ventilator settings were linked to survival.Discussion
The present study evaluated the prognostic value of mouth
occlusion pressures in patients with CHRF receiving NIV.
Baseline values of PImax and P0.1 prior to NIV were predictors
of long-term mortality, in addition to established risk
factors. Beside FEV1 and BMI, the ratio P0.1/PImax could be
identified as an independent predictor of long-term survival.
Consistent with this finding, the reduction in P0.1/PImax after
treatment including NIV was linked to reduced mortality in
patients who showed markedly elevated baseline values of
this measure.
The different pathophysiological mechanisms leading to
CHRF and the long-term prognostic value of hypercapnia are
not yet fully clear.19 A major factor in the development of
CHRF seems to be an imbalance between load and capacity
of inspiratory muscles.1,20 In patients with COPD it has been
suggested that patients with CHRF change their ventilatory
pattern into rapid shallow breathing, probably in attempt to
avoid respiratory muscle fatigue.20,21 Resting inspiratory
drive can be captured non-invasively by P0.1, which is not
biased by the conscious response to the occlusion man-
oeuvre or the mechanical properties of the lung.4 Similar to
our findings, high values of P0.1 independent of PaCO2 levels
were reported in patients with COPD, suggesting that the
central response to CO2 is preserved.
2 In invasive assessment
of diaphragm activity, even an increased neural drive was
reported in patients with severe hypercapnic COPD.22
To our knowledge, the present study is novel in assessing
P0.1 in CHRF of different origins and in evaluating its
predictive value for long-term survival. The correlation
between P0.1 and ventilatory impairment in terms of sRaw,
RV/TLC, FEV1 and FEV1/IVC supported the view that
inspiratory drive is linked to the mechanical load of the
respiratory system. Accordingly, patients with COPD or
CWD/ILD, who experienced mechanical disadvantage by
hyperinflation or decreased chest/lung compliance, showed
the highest values of P0.1. High leukocyte numbers and low
Hb levels were also revealed as correlates of increased
inspiratory drive. This seems plausible since Hb mediates
oxygen supply to respiratory muscles and elevated leukocyte
numbers often reflect airway inflammation which is accom-
panied by increased mechanical load.1
P0.1 was only slightly elevated in patients with NMD in
contrast to COPD, CWD or ILD. Possibly respiratory muscle
weakness, which was particularly pronounced in these
patients, affected the assessment of P0.1. Furthermore, in
many patients with OHS, P0.1 levels were normal despite the
mechanical load resulting from extreme obesity.23 P0.1 thus
reflected hypoventilation in these patients, which is
required by definition.13 In both NMD and OHS, no significant
changes occurred after NIV therapy.
According to univariate analyses, an elevated P0.1 was
associated with poor long-term survival in the total group of
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S. Budweiser et al.2350patients. This finding suggests that, in most patients with
chronic hypercapnia, therapeutic interventions should aim
at decreasing, not stimulating, ventilatory drive.2 Whether
NIV exerts its beneficial effects in exactly this manner is still
controversial.24–26 Noteworthy, however, patients with CWD
who are known to benefit most from NIV with respect to
long-term survival27 showed the greatest reductions in P0.1
at follow-up. Conversely, patients with ILD, in whom NIV is
of questionable efficacy and who have the worst prognosis if
hypercapnia develops, P0.1 was even increased at follow-up.
Beyond alterations in respiratory drive, respiratory
muscle weakness plays a prominent role in many patients
with CHRF.28 In COPD, not only systemic inflammation and
malnutrition but also mechanical disadvantage contributes
to the reduction in respiratory muscle strength. Accordingly,
PImax was correlated with indices of airflow obstruction and
lung hyperinflation. Our findings do not allow us to
determine to which extent the reduction in PImax resulted
from the shortening of active muscle fibre length due to
hyperinflation, or from a true reduction in respiratory
muscle force.4 The latter may well be possible, as the
diaphragm of patients with mild to moderate COPD showed
impaired contractile function due to ubiquitin-induced loss
of the myosin heavy chain.29
The value of PImax as a measure of inspiratory muscle
strength or capacity has often been questioned,3 since this
test critically depends on the patient’s cooperation. None-
theless, PImax is often used in therapeutic decisions and the
evaluation of treatment efficacy.5–8 Comparable with our
findings, PImax has also been identified as a risk factor for
mortality in COPD8,9 and neuromuscular diseases, i.e.
amyotrophic lateral sclerosis.30
In line with its known limitation, the prognostic value of
PImax in our study was lower than that of P0.1, while the ratio
P0.1/PImax was the most powerful predictor of mortality.
Consistently, a reduction in P0.1/PImax after initiation of NIV
was associated with improved survival in patients showing a
particularly high P0.1/PImax ratio at baseline. The prognostic
value of this ratio seems plausible, as far as CHRF results
from an imbalance between respiratory muscle load and
capacity.1 Thus, the P0.1/PImax ratio is likely to reflect the
major pathophysiological mechanism of CHRF. It also takes
into account the falsely low P0.1 values resulting from
hyperinflation or respiratory muscle weakness11 und could
therefore represent a promising marker in CHRF with
different underlying causes.
Although NIV is capable of unloading respiratory muscles
and has beneficial effects on respiratory muscle function,31
the reduction in P0.1/PImax was probably the result of overall
treatment. Conversely, P0.1/PImax has been suggested as a
marker for impending respiratory muscle fatigue32 and is
highly predictive during the weaning procedure.11 Using
threshold values of 0.09 and 0.14, close to our values
identified (Table 1), diagnostic accuracy was as high as 98%
in distinguishing patients who could be successfully extu-
bated from those who could not.11, 33 Beyond its predictive
value for survival as revealed in the present study, P0.1/PImax
could therefore also play a role in the decision regarding
initiation of NIV. This, however, has to be proven in
prospective controlled trials.
Our data confirmed the prognostic power of FEV1 and BMI
in patients with CHRF.19,34 Additionally, elevated leukocytenumbers predicted poor long-term survival, probably in
relation to elevated systemic inflammation or the intake of
oral corticosteroids. Noteworthy enough, leukocyte num-
bers remained a significant predictor of mortality even when
excluding patients with exacerbation upon baseline. As
blood gas parameters were mainly assessed during oxygen
supplementation, their analysis, especially that of hypox-
emia, was biased within the present study. At least the role
of hypoxemia for survival is, however, well established, and
only the relevance of hypercapnia is still controversial.19,35
To summarize, in patients with severe CHRF resulting
from various causes, mouth occlusion pressures, especially
the ratio P0.1/PImax, predicted long-term mortality under
NIV therapy. This was true for baseline values determined
prior adequate therapy including NIV, but also for its
improvements in patients with excessive baseline values.
Based on these findings, the easily and non-invasively
obtainable ratio P0.1/PImax appears to be well worth
considering in the clinical assessment of disease severity
and for monitoring purposes during long-term NIV in patients
with CHRF.Conflict of interest statement
None of the authors have any conflict of interest in the issue
covered by the manuscript.References
1. Roussos C, Koutsoukou A. Respiratory failure. Eur Respir J 2003;
47(Suppl):3s–14s.
2. Montes dO, Celli BR. Mouth occlusion pressure, CO2 response
and hypercapnia in severe chronic obstructive pulmonary
disease. Eur Respir J 1998;12:666–71.
3. Polkey MI, Green M, Moxham J. Measurement of respiratory
muscle strength. Thorax 1995;50:1131–5.
4. ATS/ERS Statement on respiratory muscle testing. Am J Respir
Crit Care Med 2002;166:518–624.
5. Clinical indications for noninvasive positive pressure ventilation
in chronic respiratory failure due to restrictive lung disease,
COPD, and nocturnal hypoventilation—a consensus conference
report. Chest 1999;116:521–34.
6. Andreas S, Herrmann-Lingen C, Raupach T, et al. Angiotensin II
blockers in obstructive pulmonary disease: a randomised
controlled trial. Eur Respir J 2006;27:972–9.
7. Budweiser S, Moertl M, Jorres RA, Windisch W, Heinemann F,
Pfeifer M. Respiratory muscle training in restrictive thoracic
disease: a randomized controlled trial. Arch Phys Med Rehabil
2006;87:1559–65.
8. Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG.
Nutritional status and mortality in chronic obstructive pulmon-
ary disease. Am J Respir Crit Care Med 1996;153:961–6.
9. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a
reversible factor in the prognosis of chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 1998;157:
1791–7.
10. van der Palen J, Rea TD, Manolio TA, et al. Respiratory muscle
strength and the risk of incident cardiovascular events. Thorax
2004;59:1063–7.
11. Capdevila XJ, Perrigault PF, Perey PJ, Roustan JP, d’Athis F.
Occlusion pressure and its ratio to maximum inspiratory
pressure are useful predictors for successful extubation follow-
ing T-piece weaning trial. Chest 1995;108:482–9.
ARTICLE IN PRESS
Mouth occlusion pressure in respiratory failure 235112. Standards for the diagnosis and care of patients with chronic
obstructive pulmonary disease. American Thoracic Society. Am
J Respir Crit Care Med 1995;152:S77–S121.
13. Olson AL, Zwillich C. The obesity hypoventilation syndrome. Am
J Med 2005;118:948–56.
14. Standardization of Spirometry, 1994 Update. American Thoracic
Society. Am J Respir Crit Care Med 1995;152:1107–36.
15. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R,
Yernault JC. Lung volumes and forced ventilatory flows. Report
Working Party Standardization of Lung Function Tests, European
Community for Steel and Coal. Official Statement of the European
Respiratory Society. Eur Respir J 1993;16(Suppl):5–40.
16. Windisch W, Hennings E, Sorichter S, Hamm H, Criee CP. Peak or
plateau maximal inspiratory mouth pressure: which is best? Eur
Respir J 2004;23:708–13.
17. Criee CP. Analysis of inspiratory mouth pressures. Prax Klin
Pneumol 1988;42(Suppl 2):820–6.
18. Budweiser S, Heinemann F, Fischer W, Dobroschke J, Pfeifer M.
Long-term reduction of hyperinflation in stable COPD by non-
invasive nocturnal home ventilation. Respir Med 2005;99:
976–84.
19. Chailleux E, Fauroux B, Binet F, Dautzenberg B, Polu JM.
Predictors of survival in patients receiving domiciliary oxygen
therapy or mechanical ventilation. A 10-year analysis of
ANTADIR Observatory. Chest 1996;109:741–9.
20. Calverley PM. Respiratory failure in chronic obstructive pul-
monary disease. Eur Respir J 2003;47(Suppl):26s–30s.
21. Gorini M, Misuri G, Corrado A, et al. Breathing pattern and
carbon dioxide retention in severe chronic obstructive pulmon-
ary disease. Thorax 1996;51:677–83.
22. De Troyer A, Leeper JB, McKenzie DK, Gandevia SC. Neural drive
to the diaphragm in patients with severe COPD. Am J Respir Crit
Care Med 1997;155:1335–40.
23. Koenig SM. Pulmonary complications of obesity. Am J Med Sci
2001;321:249–79.
24. Diaz O, Begin P, Torrealba B, Jover E, Lisboa C. Effects of
noninvasive ventilation on lung hyperinflation in stable hyper-
capnic COPD. Eur Respir J 2002;20:1490–8.25. Schonhofer B, Polkey MI, Suchi S, Kohler D. Effect of home
mechanical ventilation on inspiratory muscle strength in COPD.
Chest 2006;130:1834–8.
26. Nickol AH, Hart N, Hopkinson NS, Moxham J, Simonds A, Polkey
MI. Mechanisms of improvement of respiratory failure in
patients with restrictive thoracic disease treated with non-
invasive ventilation. Thorax 2005;60:754–60.
27. Gustafson T, Franklin KA, Midgren B, Pehrsson K, Ranstam J,
Strom K. Survival of patients with kyphoscoliosis receiving
mechanical ventilation or oxygen at home. Chest 2006;130:
1828–33.
28. Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J
Respir Crit Care Med 2003;168:10–48.
29. Ottenheijm CA, Heunks LM, Sieck GC, et al. Diaphragm
dysfunction in chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2005;172:200–5.
30. Morgan RK, McNally S, Alexander M, Conroy R, Hardiman O,
Costello RW. Use of Sniff nasal-inspiratory force to predict
survival in amyotrophic lateral sclerosis. Am J Respir Crit Care
Med 2005;171:269–74.
31. Polese G, Vitacca M, Bianchi L, Rossi A, Ambrosino N. Nasal
proportional assist ventilation unloads the inspiratory muscles
of stable patients with hypercapnia due to COPD. Eur Respir J
2000;16:491–8.
32. Criee CP. Recommendations of the German Airway League
(Deutsche Atemwegsliga) for the determination of inspiratory
muscle function. Pneumologie 2003;57:98–100.
33. Gandia F, Blanco J. Evaluation of indexes predicting
the outcome of ventilator weaning and value of adding
supplemental inspiratory load. Intensive Care Med 1992;18:
327–33.
34. Cano NJ, Pichard C, Roth H, et al. C-reactive protein and body
mass index predict outcome in end-stage respiratory failure.
Chest 2004;126:540–6.
35. Aida A, Miyamoto K, Nishimura M, Aiba M, Kira S, Kawakami Y.
Prognostic value of hypercapnia in patients with chronic
respiratory failure during long-term oxygen therapy. Am J
Respir Crit Care Med 1998;158:188–93.
